Kintara Therapeutics P/E Ratio

Kintara Therapeutics (KTRA) currently reports a P/E ratio of -4.04. That is below the Materials sector average of 15.59. Use the charts on this page to explore Kintara Therapeutics's P/E ratio history and peer comparisons.

Kintara Therapeutics's P/E ratio of -4.04 is lower than the Materials sector average of 15.59. That is roughly 125.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Kintara Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -4.04, KTRA can look expensive or cheap only in context — versus its own history, growth rate, and Materials peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -4.04, then check the historical chart for trend and the peer comparison chart for relative positioning. The Materials average is 15.59. From there, open related valuation or income-statement pages for Kintara Therapeutics, and consider following KTRA for alerts when major investors trade the stock.

Kintara Therapeutics is classified in the Materials sector. On P/E ratio, it currently shows -4.04 versus a sector average near 15.59. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Materials are usually more informative than comparing KTRA with unrelated industries.